Treatment with agalsidase beta during pregnancy in Fabry disease

被引：12

作者：

Politei, Juan M. ^{[1
]}

机构：

[1] Juan A Fernandez Hosp, Neurol & Lysosomal Disorders Serv, Buenos Aires, DF, Argentina

来源：

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH | 2010年 / 36卷 / 02期

关键词：

agalsidase beta; Fabry disease; pregnancy; ENZYME REPLACEMENT THERAPY; MANIFESTATIONS; FEMALES; ALPHA;

D O I：

10.1111/j.1447-0756.2009.01164.x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 [妇产科学];

摘要：

Fabry disease is an X-linked lysosomal storage disease caused by a deficiency of alpha-galactosidase A, which leads to excessive accumulation of glycosphingolipids in most tissues in the body, with life-threatening clinical consequences in the kidney, heart, and cerebrovascular system. Enzyme replacement therapy using exogenously produced alpha-galactosidase has been available for treatment of this multisystem progressive disease since 2001. Two different preparations of enzyme replacement therapy for Fabry disease are available outside of the USA: agalsidase alfa and agalsidase beta. Despite being X-linked, Fabry disease affects many female patients, and this report presents a successful pregnancy of a female patient receiving agalsidase beta.

引用

页码：428 / 429

页数：2

共 9 条

[1]

Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy [J].

Desnick, RJ ;

Brady, R ;

Barranger, J ;

Collins, AJ ;

Germain, DP ;

Goldman, M ;

Grabowski, G ;

Packman, S ;

Wilcox, WR .

ANNALS OF INTERNAL MEDICINE, 2003, 138 (04) :338-346

[2]

Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. [J].

Eng, CM ;

Guffon, N ;

Wilcox, WR ;

Germain, DP ;

Lee, P ;

Waldek, S ;

Caplan, L ;

Linthorst, GE ;

Desnick, RJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) :9-16

[3]

KALKUM G, 2009, EUR J OBSTET GYNECOL

[4]

Disease manifestations and X inactivation in heterozygous females with Fabry disease [J].

Maier, Esther M. ;

Osterrieder, Stephanie ;

Whybra, Catharina ;

Ries, Markus ;

Gal, Andreas ;

Beck, Michael ;

Roscher, Adelbert A. ;

Muntau, Ania C. .

ACTA PAEDIATRICA, 2006, 95 :30-38

[5]

DEMONSTRATION OF FABRYS-DISEASE DEPOSITS IN PLACENTA [J].

POPLI, S ;

LEEHEY, DJ ;

MOLNAR, ZV ;

NAWAB, ZM ;

ING, TS .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 162 (02) :464-465

[6]

Enzyme replacement therapy in Fabry disease - A randomized controlled trial [J].

Schiffmann, R ;

Kopp, JB ;

Austin, HA ;

Sabnis, S ;

Moore, DF ;

Weibel, T ;

Balow, JE ;

Brady, RO .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2743-2749

[7]

Manifestations of Fabry disease in placental tissue [J].

Vedder, AC ;

Strijland, A ;

Weerman, MAV ;

Florquin, S ;

Aerts, JMFG ;

Hollak, CEM .

JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (01) :106-111

[8]

Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa [J].

Wendt, S ;

Whybra, C ;

Kampmann, C ;

Teichmann, E ;

Beck, M .

JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (05) :787-788

[9]

Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry [J].

Wilcox, William R. ;

Oliveira, Joao Paulo ;

Hopkin, Robert J. ;

Ortiz, Alberto ;

Banikazemi, Maryam ;

Feldt-Rasmussen, Ulla ;

Sims, Katherine ;

Waldek, Stephen ;

Pastores, Gregory M. ;

Lee, Philip ;

Eng, Christine M. ;

Marodi, Laszlo ;

Stanford, Kevin E. ;

Breunig, Frank ;

Wanner, Christoph ;

Warnock, David G. ;

Lemay, Roberta M. ;

Germain, Dominique P. .

MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) :112-128

← 1 →